INHIBITION OF CLINICAL HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 ISOLATES IN PRIMARY CD4(-LYMPHOCYTES BY RETROVIRAL VECTORS EXPRESSING ANTI-HIV GENES() T)
T. Vandendriessche et al., INHIBITION OF CLINICAL HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 ISOLATES IN PRIMARY CD4(-LYMPHOCYTES BY RETROVIRAL VECTORS EXPRESSING ANTI-HIV GENES() T), Journal of virology, 69(7), 1995, pp. 4045-4052
Gene therapy may be of benefit in human immunodeficiency virus type 1
(HIV-1)-infected individuals by virtue of its ability to inhibit virus
replication and prevent viral gene expression. It is not known whethe
r anti-HIV-1 gene therapy strategies based on antisense or transdomina
nt HIV-1 mutant proteins can inhibit the replication and expression of
clinical HIV-1 isolates in primary CD4(+) T lymphocytes. We therefore
transduced CD4(+) T lymphocytes from uninfected individuals with retr
oviral vectors expressing either HIV-1-specific antisense-TAR or antis
ense-Tat/Rev RNA, transdominant HIV-1 Rev protein, and a combination o
f antisense-TAR and transdominant Rev. The engineered CD4(+) T lymphoc
ytes were then infected with four different clinical HIV-1 isolates. W
e found that replication of all HIV-1 isolates was inhibited by all th
e anti-HIV vectors tested. Greater inhibition of HIV-1 was observed wi
th transdominant Rev than,vith antisense RNA. We hereby demonstrated e
ffective protection by antisense RNA or transdominant mutant proteins
against HIV-1 infection in primary CD4(+) T lymphocytes using clinical
HIV-1 isolates, and this represents an essential step toward clinical
anti-HIV-1 gene therapy.